Skip to main content
. 2016 Aug 29;27(11):2032–2038. doi: 10.1093/annonc/mdw317

Figure 3.

Figure 3.

(A) Patients (n = 117, blue) treated with methylnaltrexone (MNTX) had a longer median overall survival (OS) compared with patients (n = 56, green) treated with placebo without subsequent crossover to MNTX (76 days, 95% CI 43–109 versus 26 days, 95% CI 17–35; P < 0.001). (B) Patients (n = 73, blue) with a response to treatment (laxation within 4 h after the first administration) had a longer median OS compared with patients (n = 100, green) without a response and crossover to MNTX (118 days, 95% CI 46–190 versus 30 days, 95% CI 23–37; P < 0.001). (C) Patients (n = 56, blue) who crossed over from placebo to MNTX had a longer median OS compared with patients (n = 56, green) treated with placebo without subsequent crossover to MNTX (75 days, 95% CI 59–91 versus 26 days, 95% CI 17–35; P < 0.001).